5
OIE Aquatic Animal Health Standards Commission/February 2014
1.4.1. Infection with ostreid herpesvirus-1 microvariant
The Aquatic Animals Commission noted that as a consequence of the proposal to delete
Article 1.2.3. ‘Criteria for listing an emerging aquatic animal disease’ (see Item 1.3.), infection with
ostreid herpesvirus-1 microvariant would be deleted from Article 1.3.2.
The Aquatic Animals Commission highlighted that infection with ostreid herpesvirus-1 microvariant
meets the definition for an emerging disease and therefore when Article 1.2.3. is deleted, the
obligation to report the occurrence of this disease would remain as per provisions of Chapter 1.1.
Notification of diseases and epidemiological information.
1.4.2. Yellow head disease
In line with the OIE approach to move towards disease names in the format of ‘infection with’ in
Chapter 9.8. ‘Yellow head disease’ of the Aquatic Code, the Aquatic Animals Commission agreed to
amend the listed name in Article 1.3.3. to: Infection with yYellow head virus disease (see Item
1.11.).
The revised Chapter 1.3. is attached as Annex 6 to be presented for adoption at the 82nd General
Session in May 2014.
1.4.3. Acute hepatopancreatic necrosis disease
The Aquatic Animals Commission reminded Member Countries that it had considered Acute
hepatopancreatic necrosis disease (AHPND) for possible listing in accordance with Article 1.2.2. at
its October 2013 meeting.
The Aquatic Animals Commission considered Member Countries’ comments and an expert’s
opinion to consider the listing of AHPND. In addition, the Commission reviewed new information
on AHPND and considered whether the disease satisfies the criteria for listing in Article 1.2.2.
The Aquatic Animals Commission considered that the publicly available information on AHPND is
insufficient to propose listing of the disease in accordance with Article 1.2.2. In particular, the
Commission reiterated the comments made in its October 2013 meeting report that there is
insufficient information to accurately characterise the causative agent of AHPND. A virulent form
of Vibrio parahaemoloyticus is considered to be the causative agent of AHPND; however, this
Vibrio species is ubiquitous and, if OIE trade standards were to be developed, it is essential that the
causative agent of AHPND can be distinguished from other forms of the bacterium. Furthermore,
there is currently no specific test available that can be used to detect the causative agent in
subclinical infections.
The Aquatic Animals Commission noted that research has been undertaken to characterise the
causative agent of AHPND and that specific diagnostic tests are under development. Information on
preliminary PCR primers have been made publically available by Drs Flegel and Lo but their
analytical specificity remains uncertain. In addition, information was provided to the Commission
by Dr Lightner that a PCR test has been developed by the University of Arizona with rights assigned
to a commercial party. However, no technical details regarding the performance of this test were
provided to the Commission. The lack of information on the analytical specificity of both assays is
of concern given the ubiquitous nature of V. parahaemoloyticus. The Commission encourages
Member Countries to provide any relevant information that would assist in the assessment for listing
against criteria in Article 1.2.2.
In addition, the Aquatic Animals Commission noted a comment from a Member Country about
reluctance they have experienced ‘from current expert laboratories to release biological materials to
investigate diagnostic methods’. The Commission encourages Member Countries and their
laboratories to share information and materials to allow the development and validation of assays for
AHPND, as for any new or emerging disease.